These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23558027)

  • 1. When to initiate intravenous therapy and/or refer.
    Champion HC
    Am J Cardiol; 2013 Apr; 111(8 Suppl):21C-4C. PubMed ID: 23558027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
    Brancaccio G; Toscano A; Bevilacqua M; Di Chiara L; Parisi F
    Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension.
    Halank M; Kolditz M; Opitz C; Hoeffken G; Ewert R
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):54-9. PubMed ID: 16489527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension.
    Gomberg-Maitland M; McLaughlin V; Gulati M; Rich S
    Am J Cardiol; 2005 Nov; 96(9):1334-6. PubMed ID: 16253609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.
    Farber HW; Miller DP; Meltzer LA; McGoon MD
    J Heart Lung Transplant; 2013 Nov; 32(11):1114-22. PubMed ID: 24035189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pulmonary arterial hypertension and systemic sclerosis].
    Launay D; Humbert M; Hachulla E
    Presse Med; 2006 Dec; 35(12 Pt 2):1929-37. PubMed ID: 17159719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging medical therapies for pulmonary arterial hypertension.
    Galiè N; Manes A; Branzi A
    Prog Cardiovasc Dis; 2002; 45(3):213-24. PubMed ID: 12525997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostanoid therapy for pulmonary arterial hypertension.
    Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sildenafil therapy for pulmonary hypertension: a prospective study].
    Lu XL; Xiong CM; Shan GL; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Zeng WJ; Zhu F; He JG
    Zhonghua Jie He He Hu Xi Za Zhi; 2011 Jun; 34(6):419-23. PubMed ID: 21781512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled iloprost in pulmonary arterial hypertension.
    Baker SE; Hockman RH
    Ann Pharmacother; 2005; 39(7-8):1265-74. PubMed ID: 15976392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.
    Hoeper MM; Markevych I; Spiekerkoetter E; Welte T; Niedermeyer J
    Eur Respir J; 2005 Nov; 26(5):858-63. PubMed ID: 16264047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension.
    Preston IR; Klinger JR; Houtches J; Nelson D; Farber HW; Hill NS
    Respir Med; 2005 Dec; 99(12):1501-10. PubMed ID: 15890512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scheduled perioperative switch from oral sildenafil to intravenous epoprostenol in a patient with Eisenmenger syndrome undergoing a sigmoidectomy.
    Moriyama K; Uzawa K; Iijima T; Kotani M; Moriyama K; Ohashi Y; Satoh T; Yorozu T
    J Clin Anesth; 2012 Sep; 24(6):487-9. PubMed ID: 22762976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension.
    Abman SH; Kinsella JP; Rosenzweig EB; Krishnan U; Kulik T; Mullen M; Wessel DL; Steinhorn R; Adatia I; Hanna B; Feinstein J; Fineman J; Raj U; Humpl T;
    Am J Respir Crit Care Med; 2013 Mar; 187(6):572-5. PubMed ID: 23220921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostacyclin therapy for pulmonary arterial hypertension: new directions.
    Gomberg-Maitland M; Preston IR
    Semin Respir Crit Care Med; 2005 Aug; 26(4):394-401. PubMed ID: 16121316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination therapy for the treatment of pulmonary arterial hypertension].
    Kähler CM
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S181-2. PubMed ID: 19718614
    [No Abstract]   [Full Text] [Related]  

  • 20. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.